Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Saro Armenian"'
Autor:
Maja V Maraldo, Mario Levis, Alessandro Andreis, Saro Armenian, James Bates, Jessica Brady, Alessandra Ghigo, Alexander R Lyon, Charlotte Manisty, Umberto Ricardi, Marianne C Aznar, Andrea Riccardo Filippi
Publikováno v:
The Lancet Haematology. 9:e445-e454
In potentially curable cancers, long-term survival depends not only on the successful treatment of the malignancy but also on the risks associated with treatment-related toxicity, especially cardiotoxicity. Malignant lymphomas affect patients at any
Autor:
Joerg Herrmann, Daniel Lenihan, Saro Armenian, Ana Barac, Anne Blaes, Daniela Cardinale, Joseph Carver, Susan Dent, Bonnie Ky, Alexander R Lyon, Teresa López-Fernández, Michael G Fradley, Sarju Ganatra, Giuseppe Curigliano, Joshua D Mitchell, Giorgio Minotti, Ninian N Lang, Jennifer E Liu, Tomas G Neilan, Anju Nohria, Rupal O'Quinn, Iskra Pusic, Charles Porter, Kerry L Reynolds, Kathryn J Ruddy, Paaladinesh Thavendiranathan, Peter Valent
Publikováno v:
Eur Heart J
The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies,
Autor:
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J E Tissing, Florent de Vathaire, Paul C Nathan, Leontien C M Kremer, Annelies M C Mavinkurve-Groothuis, Saro Armenian
Publikováno v:
de Baat, E C, van Dalen, E C, Mulder, R L, Hudson, M M, Ehrhardt, M J, Engels, F K, Feijen, E A M, Grotenhuis, H B, Leerink, J M, Kapusta, L, Kaspers, G J L, Merkx, R, Mertens, L, Skinner, R, Tissing, W J E, de Vathaire, F, Nathan, P C, Kremer, L C M, Mavinkurve-Groothuis, A M C & Armenian, S 2022, ' Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines : recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group ', The Lancet Child and Adolescent Health, vol. 6, no. 12, pp. 885-894 . https://doi.org/10.1016/S2352-4642(22)00239-5
The Lancet Child & Adolescent Health, 6, 885-894
The Lancet Child & Adolescent Health, 6, 12, pp. 885-894
The Lancet Child & Adolescent Health, 6, 885-894
The Lancet Child & Adolescent Health, 6, 12, pp. 885-894
Item does not contain fulltext Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane, and little guidance is available on it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e933dd197d23cbe7070b694086dff1e7
https://doi.org/10.1016/S2352-4642(22)00239-5
https://doi.org/10.1016/S2352-4642(22)00239-5